INTELLIGENT SOLUTIONS FOR ORAL DRUG DELIVERY Trademark

Trademark Overview

On Friday, August 2, 2013, a trademark application was filed for INTELLIGENT SOLUTIONS FOR ORAL DRUG DELIVERY with the United States Patent and Trademark Office. The USPTO has given the INTELLIGENT SOLUTIONS FOR ORAL DRUG DELIVERY trademark a serial number of 86027630. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, February 28, 2025. This trademark is owned by Enteris BioPharma, Inc.. The INTELLIGENT SOLUTIONS FOR ORAL DRUG DELIVERY trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development of oral drug formulations and pharmaceuticals
intelligent solutions for oral drug delivery

General Information

Serial Number86027630
Word MarkINTELLIGENT SOLUTIONS FOR ORAL DRUG DELIVERY
Filing DateFriday, August 2, 2013
Status710 - CANCELLED - SECTION 8
Status DateFriday, February 28, 2025
Registration Number4585895
Registration DateTuesday, August 12, 2014
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 1, 2014

Trademark Statements

NOT AVAILABLE"ORAL DRUG DELIVERY"
Goods and ServicesResearch and development of oral drug formulations and pharmaceuticals

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, February 28, 2025
Primary Code042
First Use Anywhere DateThursday, February 6, 2014
First Use In Commerce DateThursday, February 6, 2014

Trademark Owner History

Party NameEnteris BioPharma, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressBoonton, NJ 07005
Party NameEnteris BioPharma, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBoonton, NJ 07005
Party NameEnteris BioPharma, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBoonton, NJ 07005

Trademark Events

Event DateEvent Description
Monday, November 18, 2013ASSIGNED TO EXAMINER
Monday, November 18, 2013NON-FINAL ACTION WRITTEN
Saturday, August 10, 2013NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, November 18, 2013NON-FINAL ACTION MAILED
Monday, February 3, 2014APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, February 21, 2014ASSIGNED TO LIE
Friday, February 21, 2014LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, March 12, 2014NOTICE OF PUBLICATION
Tuesday, April 1, 2014PUBLISHED FOR OPPOSITION
Tuesday, May 27, 2014NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 3, 2014TEAS STATEMENT OF USE RECEIVED
Tuesday, June 3, 2014USE AMENDMENT FILED
Thursday, January 30, 2014TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, January 30, 2014CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, January 31, 2014TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, June 30, 2014CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, July 2, 2014STATEMENT OF USE PROCESSING COMPLETE
Friday, July 11, 2014NOTICE OF ACCEPTANCE OF STATEMENT OF USE MAILED
Tuesday, August 12, 2014REGISTERED-PRINCIPAL REGISTER
Thursday, July 18, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, July 10, 2014ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, July 18, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, August 12, 2019COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Saturday, August 12, 2023COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Friday, February 28, 2025CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9
Wednesday, August 5, 2020NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Monday, May 18, 2020TEAS SECTION 8 & 15 RECEIVED
Wednesday, August 5, 2020CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Wednesday, August 5, 2020REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.

Related Keywords

delivery drug oral solutions intelligent formulations pharmaceuticals development research